Početna › Kolorektalni rak › Oklahoma
Kliničke studije za Kolorektalni rak u državi Oklahoma
22 studija za Kolorektalni rak traži sudionike na lokacijama u državi Oklahoma.
Gradovi u državi Oklahoma
Službeni tekst studije (engleski)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- University of Oklahoma, Oklahoma City
U tijeku regrutacijaFaza 1/2
Od 12 godina i više · Oba spola · Ažurirano 2. lis 2026. · NCT04585750Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Hospital Oklahoma City, Oklahoma City
U tijeku regrutacijaOpažajna studijaZdravi dobrovoljci dobrodošli
Od 40 do 75 godina · Oba spola · Ažurirano 2. lis 2026. · NCT05334069Family Communications After Genetic Testing
- Mercy Hospital Oklahoma City, Oklahoma City
U tijeku regrutacijaZdravi dobrovoljci dobrodošli
Od 18 godina i više · Oba spola · Ažurirano 2. lis 2026. · NCT07143487Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
- University of Oklahoma Health Sciences Center, Oklahoma City
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 29. ruj 2026. · NCT05803382Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 23. ruj 2026. · NCT06102902Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- University of Oklahoma, Oklahoma City
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT06128551Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- Stephenson Cancer Center, Oklahoma City
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT06445062Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 9. ruj 2026. · NCT06696768Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
- Clinical Study Site, Oklahoma City
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 8. ruj 2026. · NCT07228832The Vanguard Study: Testing a New Way to Screen for Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
U tijeku regrutacijaZdravi dobrovoljci dobrodošli
Od 45 do 75 godina · Oba spola · Ažurirano 2. ruj 2026. · NCT06995898A Study of DM002 in Patients With Advanced Solid Tumors
- University of Oklahoma Health Sciences Center, Oklahoma City
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 7. kol 2026. · NCT06751329Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
- University of Oklahoma Health Sciences Center, Oklahoma City
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 31. srp 2026. · NCT05691491A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Stephenson Cancer Center, Oklahoma City
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 30. srp 2026. · NCT04657068Feasibility of a Multi-Channel Intervention to Promote Colorectal Cancer Screening Among American Indians in Oklahoma
- TSET Health Promotion Research Center, Oklahoma City
U tijeku regrutacija
Od 45 do 75 godina · Oba spola · Ažurirano 30. srp 2026. · NCT07254910A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- SSM OKC Hightower Clinical, Oklahoma City
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 29. srp 2026. · NCT03526835Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy
- Hightower Clinical, Oklahoma City
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 15. srp 2026. · NCT06937177Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
- Mercy Hospital - OKC, Oklahoma City
U tijeku regrutacijaOpažajna studija
Od 18 godina i više · Oba spola · Ažurirano 29. lip 2026. · NCT07327489KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
- OU Stephenson Cancer Center, Oklahoma City
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 8. lip 2026. · NCT06026410A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
- OU Health Stephenson Cancer Center, Oklahoma City
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 23. tra 2026. · NCT06720987Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors
- Mercy Hospital Oklahoma City, Oklahoma City
U tijeku regrutacijaFaza 3Zdravi dobrovoljci dobrodošli
Od 18 godina i više · Oba spola · Ažurirano 31. ožu 2026. · NCT07018869Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Mercy Hospital Oklahoma City, Oklahoma City
U tijeku regrutacijaOpažajna studija
Od 18 godina i više · Oba spola · Ažurirano 17. ožu 2026. · NCT06418204Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays
- Mercy Clinic Oncology and Hematology - Coletta, Oklahoma City
U tijeku regrutacijaOpažajna studija
Od 18 godina i više · Oba spola · Ažurirano 6. svi 2025. · NCT05234177Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.